权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

ATAC-ing dopaminergic cell identity with single-cell resolution

ATAC-ing 多巴胺能细胞识别与单细胞分辨率

基本信息

批准号：
9980840
负责人：
Adrian Rothenfluh
金额：
$ 22.88万
依托单位：
UNIVERSITY OF UTAH
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9980840
关键词：
ATAC-seq Abstinence Anatomy Award Basic Science Behavioral Bilateral Biological Process Brain Cell Nucleus Cells Characteristics Chromatin Chronic Consumption Cues DNA Data Development Disease Dopamine Dopaminergic Cell Dropout Drosophila genus Drug usage Engineering Enhancers Food Gene Expression Generations Genes Genetic Genetic Enhancer Element Genomics Goals Grant Human Individual Intake Investigational Therapies Label Learning Mammals Mediating Neurons Organism Pathway interactions Pattern Pharmaceutical Preparations Physiological Population Process Psychological reinforcement Relapse Reproduction Research Resolution Rewards Role Selection Criteria Sensitivity and Specificity Signal Transduction Specific qualifier value Specificity Substance Use Disorder Substance abuse problem Surveys System Techniques Testing Therapeutic Intervention Training Transcription Coactivator Transgenes Transgenic Animals Translating Water Whole Organism XCL1 gene addiction base cell type combinatorial craving dopaminergic neuron drug of abuse drug withdrawal genome-wide high risk improved in silico in vivo indexing learning extinction novel personalized intervention relapse risk relating to nervous system response sensory stimulus single cell analysis tool transcription factor

项目摘要

Dopamine neurons are a critical component of reward pathways in the brain. Historically, dopamine neurons were considered a relatively homogeneous population mediating association of reinforcement signals from food, water, and reproduction with coinciding sensory stimuli. However, recent studies have shown that these neurons form subpopulations with distinct physiological profiles, neural projections, and biological functions. These distinct subpopulations also have different roles in the progression of the addiction cycle, from use to abuse, abstinence and relapse. The goal of this application is to engineer novel genetic tools that will allow precise manipulation of distinct subpopulations of dopamine circuits, with specificity down to single pairs of neurons. To this end we will first apply a new technique, single-cell ATAC-seq, to determine all open chromatin/accessible DNA enhancer elements of every one of the ~250 dopamine neurons in the Drosophila brain. Second, we will determine which open enhancer fragments, or combinations thereof, will uniquely identify single dopamine cells/cell-types. And third, based on this analysis, we will engineer numerous new genetic tools and test them for their in vivo efficacy and specificity. While these Aims are linear and fully interdependent, the grant overall applies the very new technique of single-cell ATAC-seq to “break new ground” and “accelerate the pace of discoveries to advance addiction research”. The proposal essentially tests the hypothesis that this unbiased, genome-wide approach can be harnessed to generate new tools for precision intervention. Because the approach itself can be scaled, applied to any cell type, and translated to mammals, this application is fully consistent with the spirit of the Cutting-Edge Basic Research Awards (CEBRA) mechanism, which will “support high-risk, high impact research” (PAR-18-437).

多巴胺神经元是大脑中奖赏通路的关键组成部分。历史上，多巴胺神经元被认为是一个相对同质的人口介导的强化信号的关联，食物、水和生殖与感官刺激相一致。然而，最近的研究表明，神经元形成具有不同生理特征、神经投射和生物功能的亚群。这些不同的亚群在成瘾周期的进展中也有不同的作用，从使用到使用。滥用、禁欲和复发。这项应用的目标是设计新的遗传工具，精确操纵多巴胺回路的不同亚群，特异性低至单对，神经元为此，我们将首先应用一种新的技术，单细胞ATAC-seq，以确定所有开放的果蝇中约250个多巴胺神经元中每一个的染色质/可接近的DNA增强子元件个脑袋第二，我们将确定哪些开放增强子片段或其组合将独特地识别单个多巴胺细胞/细胞类型。第三，基于这一分析，我们将设计许多新的基因工具，并测试它们的体内功效和特异性。虽然这些目标是线性的，相互依存，赠款整体应用单细胞ATAC-seq的新技术，以“打破新的地面”和“加快发现的步伐，推进成瘾研究”。该提案基本上测试了这种无偏见的全基因组方法可以用来产生新的工具，精准干预因为该方法本身可以扩展，应用于任何细胞类型，并转化为哺乳动物，这项申请完全符合尖端基础研究奖的精神（CEBRA）机制，将“支持高风险、高影响的研究”（PAR-18-437）。